Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (the “Agreement”) is made as of November 16, 2009 (the “Effective Date”), by and between ADIMAB, INC., a Delaware corporation having an address at 16 Cavendish Court, Lebanon, NH 03766 (“Adimab”) and MERRIMACK PHARMACEUTICALS, INC., a Massachusetts corporation having an address at One Kendall Square, Suite B7201, Cambridge, MA 02139 (“Merrimack”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AMENDED AND RESTATED COLLABORATION AGREEMENTCollaboration Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This AMENDED AND RESTATED COLLABORATION AGREEMENT (“Agreement”), effective as of January 24, 2007 (the “Effective Date”), is between DYAX CORP., a Delaware corporation, with offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. (“Dyax”), and MERRIMACK PHARMACEUTICALS, INC., a Massachusetts corporation with its principal place of business located at One Kendall Square, Building 700, 2nd Floor, Cambridge, MA 02139, U.S.A. (“Merrimack”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. ASSIGNMENT, SUBLICENSE AND COLLABORATION AGREEMENT by and between PHARMAENGINE, INC. and MERRIMACK PHARMACEUTICALS (BERMUDA) LTD.Assignment, Sublicense and Collaboration Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • New York
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisk denote omissions. EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and HERMES BIOSCIENCES, INC. for [**] (UC Case...Exclusive License Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • California
This license agreement (“Agreement”) is made effective this 1st day of November, 2000 (“Effective Date”), between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”), and Hermes Biosciences, Inc., a California corporation, having a principal place of business at 61 Airport Boulevard, Suite B, South San Francisco, California 94080 (“Licensee”).
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and MERRIMACK PHARMACEUTICALS, INC. for [**] (UC Case No. [**]) [**] (UC Case No. [**]) and [**] (UC Case No. [**])Exclusive License Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • California
This license agreement (“Agreement”) is made effective this 16th day of March, 2005 (“Effective Date”), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”) and Merrimack Pharmaceuticals, Inc., a Massachusetts corporation, having a principal place of business at 101 Binney Street, Cambridge, Massachusetts 02142 (“Licensee”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AGREEMENT Between Hermes Biosciences, Inc. And PharmaEngine, Inc. Dated As of September 26, 2005License Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • California
GENERAL. As used in this Agreement, unless context dictates otherwise, the following terms shall have the meanings set forth in this Article 1 and words denoting the singular shall include the plural and vice versa.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENT By and Between SANOFI-AVENTIS and MERRIMACK PHARMACEUTICALS, INC.License and Collaboration Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This License and Collaboration Agreement (this “Agreement”), dated the 30th day of September, 2009 (the “Execution Date”), is by and between SANOFI-AVENTIS, a French corporation with its principal offices at 174 avenue de France, 75013 Paris, France (“SANOFI-AVENTIS”), and MERRIMACK PHARMACEUTICALS, INC., a Massachusetts corporation with its principal offices at One Kendall Square, Suite B7201, Cambridge, MA 02139-1670, U.S.A. (“MERRIMACK”).
Confidential Materials omitted and filed separately with the Securities and Exchang Commission. Asterisks denote omissions. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT — NONEXCLUSIVE COVER PAGEPatent License Agreement • October 26th, 2011 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
